Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Breckenridge

Showing results (1-10 of 140) with videos related to

Pageof 14
Sort By:
British Journal of Clinical Pharmacology|March 29, 2012
Interactions with warfarinA Breckenridge
Hypertension (Dallas, Tex. : 1979)|September 1, 1983
Compliance of hypertensive patients with pharmacological treatmentA Breckenridge
British Medical Journal|February 21, 1976
Oral anticoagulants--the totem and the tabooA Breckenridge
British Journal of Clinical Pharmacology|March 1, 1991
Clinical Pharmacology in the United Kingdom--a view for the 1990sA Breckenridge
Clinical Pharmacology and Therapeutics|July 22, 2010
Regulatory challenges, reimbursement, and risk-benefit assessmentA Breckenridge
British Journal of Clinical Pharmacology|July 1, 1996
A clinical pharmacologist's view of drug toxicityA Breckenridge
Acta Pharmacologica Et Toxicologica|January 1, 1971
Pathophysiological factors influencing drug kineticsA Breckenridge
British Medical Journal (Clinical Research Ed.)|April 2, 1983
Which beta blocker?A Breckenridge
Clinical Pharmacology and Therapeutics|November 29, 2007
Post-marketing strategies for medicinesA Breckenridge
Basic Life Sciences|January 1, 1975
Clinical implications of enzyme inductionA Breckenridge
Pageof 14

Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
British Journal of Clinical Pharmacology|March 29, 2012
Interactions with warfarinA Breckenridge
Hypertension (Dallas, Tex. : 1979)|September 1, 1983
Compliance of hypertensive patients with pharmacological treatmentA Breckenridge
British Medical Journal|February 21, 1976
Oral anticoagulants--the totem and the tabooA Breckenridge
British Journal of Clinical Pharmacology|March 1, 1991
Clinical Pharmacology in the United Kingdom--a view for the 1990sA Breckenridge
Clinical Pharmacology and Therapeutics|July 22, 2010
Regulatory challenges, reimbursement, and risk-benefit assessmentA Breckenridge
British Journal of Clinical Pharmacology|July 1, 1996
A clinical pharmacologist's view of drug toxicityA Breckenridge
Acta Pharmacologica Et Toxicologica|January 1, 1971
Pathophysiological factors influencing drug kineticsA Breckenridge
British Medical Journal (Clinical Research Ed.)|April 2, 1983
Which beta blocker?A Breckenridge
Clinical Pharmacology and Therapeutics|November 29, 2007
Post-marketing strategies for medicinesA Breckenridge
Basic Life Sciences|January 1, 1975
Clinical implications of enzyme inductionA Breckenridge
Pageof 14